IceCure Medical's ProSense® cryoablation system demonstrated high effectiveness and safety in treating small tumors, including breast cancer, kidney cancer, and fibroadenomas, with clinical data showing up to 89.4% recurrence-free rates and significant tumor volume reduction. Presented at the 2026 European Conference on Interventional Oncology, ProSense® gained notable attention for its minimally invasive approach, FDA clearance for early-stage breast cancer, and potential to become a standard treatment alternative to surgery. The technology's ease of use and quick recovery times are driving growing global adoption and expanding clinical validation.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Garmin introduced the G2000 PRIME, a new integrated flight deck designed for high-performance Class I/II piston and electric aircraft. It features large, edge-to-edge touchscreen displays with advanced multi-touch capabilities, faster processors, and...
UniFirst Corporation has been recognized on Selling Power's 60 Best Companies to Sell For list for the 23rd consecutive year, highlighting its strong sales culture and support for sales professionals. The list evaluates companies on compensation, tra...
The global Reactive Hot Melt Adhesives market is projected to grow from USD 2.02 billion in 2025 to USD 4.29 billion by 2035, at a CAGR of 7.72%. Growth is fueled by regulations limiting solvent adhesives, increased use of polyurethane adhesives in a...
Montero Mining completed drillhole MON-ELV-02 to 625.25 meters at its Elvira Gold Project in Chile, successfully testing its top exploration target. The hole confirmed predicted volcanic and porphyry sequences with extensive pyrite and high-sulphidat...
